MRUS MERUS B V

Merus to Present at Citi's 2025 Virtual Oncology Leadership Summit

Merus to Present at Citi's 2025 Virtual Oncology Leadership Summit

UTRECHT, The Netherlands and CAMBRIDGE, Mass., Feb. 13, 2025 (GLOBE NEWSWIRE) -- . (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced that Bill Lundberg, M.D., President, Chief Executive Officer of Merus, will present at Citi's 2025 Virtual Oncology Leadership Summit on Thursday, February 20, 2025 at 9:00 a.m. ET.

The webcast of the presentation will be contemporaneously available on the of the Company's website. The archived presentation will also be available there for a limited time after the event.

About Merus

is a clinical-stage oncology company developing innovative full-length human bispecific and trispecific antibody therapeutics, referred to as . Multiclonics® are manufactured using industry standard processes and have been observed in preclinical and clinical studies to have several of the same features of conventional human monoclonal antibodies, such as long half-life and low immunogenicity. For additional information, please visit and .

Multiclonics®, Biclonics® and Triclonics® are registered trademarks of Merus N.V.



Investor and Media Inquiries:
Sherri Spear
Merus N.V.
SVP Investor Relations and Strategic Communications
617-821-3246
 

Kathleen Farren
Merus N.V.
Assoc. Director IR/Corp Comms
617-230-4165
EN
13/02/2025

Underlying

MRUSMERUS B V

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on MERUS B V

 PRESS RELEASE
Free
MRUS MERUS B V

Petosemtamab granted Breakthrough Therapy designation by the U.S. FDA ...

Petosemtamab granted Breakthrough Therapy designation by the U.S. FDA for 1L PD-L1 positive head and neck squamous cell carcinoma This marks the second BTD for petosemtamab in HNSCC UTRECHT, The Netherlands and CAMBRIDGE, Mass., Feb. 18, 2025 (GLOBE NEWSWIRE) --  (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies and antibody drug conjugates (Biclonics®, Triclonics® and ADClonics®), for cancer, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation (BTD) to petosemtamab in c...

11h / 56m 1 EN
 PRESS RELEASE
Free
MRUS MERUS B V

Merus wird beim 2025 Virtual Oncology Leadership Summit von Citi eine ...

Merus wird beim 2025 Virtual Oncology Leadership Summit von Citi eine Präsentation halten UTRECHT, Niederlande und CAMBRIDGE, Massachusetts, Feb. 13, 2025 (GLOBE NEWSWIRE) -- . (Nasdaq: MRUS), ein im klinischen Stadium tätiges Onkologieunternehmen, das innovative multispezifische Antikörper in voller Länge (Biclonics® und Triclonics®) entwickelt, hat heute bekannt gegeben, dass Dr. Bill Lundberg, President und Chief Executive Officer von Merus, am Donnerstag, den 20. Februar 2025, um 9 Uhr ET im Rahmen des 2025 Virtual Oncology Leadership Summit von Citi eine Präsentation vorstellen wird....

February 13, 2025 1 EN
 PRESS RELEASE
Free
MRUS MERUS B V

Merus fera une présentation lors du Citi's 2025 Virtual Oncology Leade...

Merus fera une présentation lors du Citi's 2025 Virtual Oncology Leadership Summit UTRECHT, Pays-Bas et CAMBRIDGE, Massachusetts, 13 févr. 2025 (GLOBE NEWSWIRE) -- . (Nasdaq : MRUS), une société d’oncologie au stade clinique développant des anticorps de pleine longueur multispécifiques et novateurs (Biclonics® et Triclonics®), annonce aujourd’hui que Bill Lundberg, M.D., Président et directeur général de Merus, fera une présentation lors du Citi's 2025 Virtual Oncology Leadership Summit le jeudi 20 février 2025, à 9 h, heure de l’Est (« HE »). Le webcast de la présentation sera accessibl...

February 13, 2025 1 EN
 PRESS RELEASE
Free
MRUS MERUS B V

Merus to Present at Citi's 2025 Virtual Oncology Leadership Summit

Merus to Present at Citi's 2025 Virtual Oncology Leadership Summit UTRECHT, The Netherlands and CAMBRIDGE, Mass., Feb. 13, 2025 (GLOBE NEWSWIRE) -- . (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced that Bill Lundberg, M.D., President, Chief Executive Officer of Merus, will present at Citi's 2025 Virtual Oncology Leadership Summit on Thursday, February 20, 2025 at 9:00 a.m. ET. The webcast of the presentation will be contemporaneously available on the of the Company's website. Th...

February 13, 2025 1 EN
 PRESS RELEASE
Free
MRUS MERUS B V

New England Journal of Medicine Publishes: Efficacy of Zenocutuzumab i...

New England Journal of Medicine Publishes: Efficacy of Zenocutuzumab in NRG1 Fusion-Positive Cancer UTRECHT, The Netherlands and CAMBRIDGE, Mass., Feb. 05, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced that the New England Journal of Medicine (NEJM) published results of the registrational phase 2 eNRGy trial for Bizengri® (zenocutuzumab), the first and only treatment indicated for adults with pancreatic adenocarcinoma or n...

February 5, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch